QRG Capital Management Inc. Purchases 325 Shares of Medpace Holdings, Inc. $MEDP

QRG Capital Management Inc. lifted its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 2.5% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 13,375 shares of the company’s stock after purchasing an additional 325 shares during the period. QRG Capital Management Inc.’s holdings in Medpace were worth $4,198,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also added to or reduced their stakes in the business. Invesco Ltd. boosted its position in Medpace by 9.4% during the 1st quarter. Invesco Ltd. now owns 1,186,768 shares of the company’s stock worth $361,596,000 after buying an additional 102,015 shares during the period. Mawer Investment Management Ltd. bought a new stake in shares of Medpace in the first quarter worth $212,131,000. Bessemer Group Inc. increased its holdings in Medpace by 1.1% in the first quarter. Bessemer Group Inc. now owns 582,269 shares of the company’s stock valued at $177,411,000 after purchasing an additional 6,225 shares during the period. AQR Capital Management LLC raised its position in Medpace by 12.4% during the 1st quarter. AQR Capital Management LLC now owns 539,547 shares of the company’s stock worth $158,470,000 after purchasing an additional 59,361 shares during the last quarter. Finally, Northern Trust Corp lifted its holdings in Medpace by 36.0% during the 1st quarter. Northern Trust Corp now owns 337,489 shares of the company’s stock worth $102,830,000 after buying an additional 89,347 shares during the period. Institutional investors own 77.98% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on MEDP. Deutsche Bank Aktiengesellschaft increased their price target on Medpace from $270.00 to $430.00 and gave the company a “hold” rating in a research note on Wednesday, July 23rd. TD Cowen restated a “sell” rating and set a $366.00 price target (up previously from $283.00) on shares of Medpace in a report on Wednesday, July 23rd. Rothschild Redb lowered shares of Medpace from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, September 3rd. Robert W. Baird increased their price objective on shares of Medpace from $313.00 to $490.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 23rd. Finally, Mizuho boosted their target price on shares of Medpace from $328.00 to $510.00 and gave the company an “outperform” rating in a report on Friday, July 25th. Three research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $422.27.

Insider Buying and Selling at Medpace

In other Medpace news, CFO Kevin M. Brady sold 12,000 shares of the stock in a transaction that occurred on Thursday, July 24th. The stock was sold at an average price of $454.23, for a total value of $5,450,760.00. Following the transaction, the chief financial officer owned 6,000 shares in the company, valued at approximately $2,725,380. This represents a 66.67% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO August J. Troendle sold 48,487 shares of the business’s stock in a transaction that occurred on Monday, July 28th. The shares were sold at an average price of $451.69, for a total value of $21,901,093.03. Following the sale, the chief executive officer owned 962,615 shares of the company’s stock, valued at approximately $434,803,569.35. This represents a 4.80% decrease in their position. The disclosure for this sale can be found here. Insiders sold 161,266 shares of company stock worth $74,111,427 in the last quarter. Company insiders own 20.30% of the company’s stock.

Medpace Stock Down 0.4%

NASDAQ:MEDP opened at $530.30 on Tuesday. Medpace Holdings, Inc. has a twelve month low of $250.05 and a twelve month high of $547.15. The company has a fifty day moving average of $476.38 and a 200-day moving average of $369.78. The firm has a market capitalization of $14.90 billion, a P/E ratio of 39.43, a P/E/G ratio of 3.35 and a beta of 1.40.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings results on Monday, July 21st. The company reported $3.10 EPS for the quarter, topping analysts’ consensus estimates of $3.00 by $0.10. Medpace had a net margin of 18.74% and a return on equity of 67.66%. The business had revenue of $603.31 million during the quarter, compared to analysts’ expectations of $537.70 million. During the same period last year, the company posted $2.75 earnings per share. The business’s quarterly revenue was up 14.2% on a year-over-year basis. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. On average, analysts anticipate that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.